Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LOP 628

Next Previous
Drug Profile

LOP 628

Alternative Names: Anti-c-kit humanised IgG1/κ antibody-maitansine conjugate - Novartis; Anti-c-kit humanised IgG1/κ antibody-maytansine conjugate - Novartis; Anti-proto-oncogene protein c-kit IgG1/kappa antibody-maitansine conjugate - Novartis; Anti-proto-oncogene protein c-kit IgG1/kappa antibody-maytansine conjugate - Novartis

Latest Information Update: 14 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 12 Feb 2024 ImmunoGen has been acquired by AbbVie
  • 01 Mar 2015 Novartis suspends phase I trial in Solid tumours and Acute myeloid leukaemia in the USA, Australia and Netherlands (NCT02221505)
  • 01 Dec 2014 Phase-I clinical trials in Acute myeloid leukaemia in USA, Australia and the Netherlands (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top